Document:

WMGI-12.31.2012-10K-Ex 10.33

Exhibit 10.33
	
			
	Name : Girin, Pascal

	 
	 

	Date : November 26, 2012

	 
	 

	Number of Options : 184500

	 
	 

	Price : $ 21.24

	 
	 

WRIGHT MEDICAL GROUP, INC.
Inducement Stock Option Grant Agreement

	
		
	Award Granted to (“Grantee”):
	 

	Grant Date:
	 

	Number of Shares (“Shares”):
	 

	Option Price:
	 

THIS INDUCEMENT STOCK OPTION GRANT AGREEMENT (the “Agreement”) is made as of the Grant Date by and between Wright Medical Group, Inc., a Delaware corporation with its principal place of business at 5677 Airline Road, Arlington, Tennessee 38002 (the “Company”) and Grantee pursuant to the terms of this Agreement.

WHEREAS, the Compensation Committee of the Board of Directors of the Company (the "Board") has decided to grant the option and right to purchase the Company`s Common Stock (the "Stock") to induce Grantee to commence employment with the Company and/or a Related Entity (as defined in this Agreement), to strengthen Grantee`s commitment to the welfare of the Company, and to promote an identity of interest between the Company`s stockholders and Grantee; and

WHEREAS, pursuant to this Agreement the Compensation Committee of the Board has authorized that Grantee be granted the right and option to purchase from the Company the Shares of Stock subject to the terms and restrictions stated below.

NOW, THEREFORE, the parties agree as follows:
1.     Definitions. Terms defined in this Agreement, including the introduction and recitals, shall have the meaning set forth herein. The following definitions shall be applicable to this Agreement:
1.1.         "Cause" shall mean the Company or a Related Entity having cause to terminate Grantee`s  employment or service in accordance with the provisions of any existing employment, consulting or any other agreement between Grantee and the Company or a Related Entity or, in the absence of such an employment, consulting or other agreement, upon (i) the determination by the Committee that Grantee has ceased to perform Grantee's duties to the Company or a Related Entity (other than as a result of Grantee's incapacity due to physical or mental illness or injury), which failure amounts to intentional and extended neglect of Grantee's duties, (ii) the Committee's determination that Grantee has engaged or is about to engage in conduct injurious to the Company or a Related Entity, or (iii) Grantee having plead no contest to a charge of a felony or having been convicted of a felony.
1.2.         "Committee" shall mean the full Board, the Compensation Committee of the Board, or such other committee that the Board may appoint to administer this Agreement.
1.3.         "Change of Control" shall mean the first to occur on or after the Grant Date of any of the following:
(a)           The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more (on a fully diluted basis) of either (A) the then outstanding shares of Stock, taking into account as outstanding for this purpose such Stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Stock (the "Outstanding Company Common Stock") or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control:  (x) any acquisition by the Company or any “affiliate” of the Company, within the meaning of 17 C.F.R. § 230.405 (an “Affiliate”), (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate, or (z) any acquisition by any corporation or business entity pursuant to a transaction which complies with clauses (A) and (B) of subsection (a) 

of this Section 1.3 (persons and entities described in clauses (x), (y), and (z) being referred to herein as “Permitted Holders”); 
(b)           The consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company`s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any Permitted Holder) beneficially owns, directly or indirectly, 50% or more (on a fully diluted basis) of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination, taking into account as outstanding for this purpose such common stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such common stock, or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the incumbent Board at the time of the execution of the initial agreement providing for such Business Combination;
(c)           The approval by the stockholders of the Company of a complete liquidation or dissolution of the Company;
(d)           The sale of at least 80% of the assets of the Company to an unrelated party, or completion of a transaction having a similar effect; or
(e)           The individuals who on the date of this Agreement constitute the Board thereafter cease to constitute at least a majority thereof; provided that any person becoming a member of the Board subsequent to the date of this Agreement and whose election or nomination was approved by a vote of at least two-thirds of the directors who then comprised the Board immediately prior to such vote shall be considered a member of the Board on the date of this Agreement.
1.4.         "Code" means the Internal Revenue Code of 1986, as amended. Reference in this Agreement to any section of the Code shall be deemed to include any amendments or successor provisions to such section and any regulations under such section.
1.5.         "Disability" shall mean the complete and permanent inability by reason of illness or accident to perform the duties of the occupation at which Grantee was employed or served when such disability commenced or, if Grantee was retired when such disability commenced, the inability to engage in any substantial gainful activity, in either case as determined by the Committee based upon medical evidence acceptable to it.
1.6.         "Eligible Person" shall mean (i) a person regularly employed by the Company or any Related Entity; provided, however, that no such employee covered by a collective bargaining agreement shall be an Eligible Person unless and to the extent that such eligibility is set forth in such collective bargaining agreement or in an agreement or instrument related thereto, (ii) director of the Company or any Related Entity; or (iii) consultant to the Company or any Related Entity.
1.7.         "Fair Market Value" on a given date shall mean (i) if the Stock is listed on a national securities exchange, the closing price of a share of Stock reported as having occurred on the primary exchange with which the Stock is listed and traded on the date prior to such date, or, if there is no such sale on that date, then on the last preceding date on which such a sale was reported; (ii) if the Stock is not listed on any national securities exchange but is quoted on an automated quotation system, the closing price of a share of Stock reported on the date prior to such date, or, if there is no such sale on that date, then on the last preceding date on which a sale was reported; or (iii) if the Stock is not listed on a national securities exchange nor quoted on an automated quotation system, the amount determined pursuant to one of the methods set forth in Treas. Reg. § 1.409A-1(b)(5)(iv)(B)(2), as elected by the Committee.
1.8.         "Related Entity" shall mean means, when referring to a subsidiary, any business entity (other than the Company) which, at the Grant Date, is in an unbroken chain of entities ending with the Company, if stock or voting 

interests possessing 50% or more of the total combined voting power of all classes of stock or other ownership interests of each of the entities other than the Company is owned by one of the other entities in such chain and, when referring to a parent entity, the term “Related Entity” shall mean any entity in an unbroken chain of entities ending with the Company if, at the Grant Date, each of the entities other than the Company owns stock or other ownership interests possessing 50% or more of the total combined voting power of all classes of stock (or other ownership interests) in one of the other entities in such chain. 
2.     Grant of Options.  Subject to the terms and conditions of this Agreement, the Company hereby grants to Grantee the right and option (the right to purchase any one share of Stock under this Agreement being an “Option”) during the period commencing on the Grant Date and, subject to Section 4 of this Agreement, ending on the 10th anniversary of the Grant Date (the “Expiration Date”) to purchase from the Company the Shares.  Each Option shall have an exercise price per share equal to the Option Price indicated above. The Options are not designated as incentive stock options within the meaning of Section 422 of the Code. 
3.     Vesting Schedule.  The Options shall vest as to one-fourth (1/4) of the Shares on the first anniversary of the Grant Date, and as to an additional one-fourth (1/4) on each succeeding anniversary date, so as to be 100% vested on the fourth anniversary of the Grant Date, conditioned upon Grantee maintaining status as an Eligible Person as of each vesting date.  Notwithstanding the foregoing, (A) the interest of Grantee to the Options shall vest as to 100% of the then unvested Options upon a Change of Control, and (B) the Committee may in its sole discretion accelerate the exercisability of the Options, provided that such acceleration shall not affect the terms and conditions of any such Options other than with respect to exercisability.
4.     Expiration of Options. The Option shall expire and cease to be exercisable at the earlier to occur, as to any share of Stock, when Grantee purchases the share or the Expiration Date. Notwithstanding the foregoing, if prior to the Expiration Date Grantee ceases to be an Eligible Person, unless otherwise determined by the Compensation Committee, the Options shall expire on the earlier of the Expiration Date or the date that is ninety days after the date upon which Grantee ceased to be an Eligible Person. In such event, the Options shall remain exercisable by Grantee until expiration only to the extent the Options were exercisable at the time that Grantee ceased to be an Eligible Person.  
5.     Restrictions.
5.1.         Except as specifically authorized by the Committee, Grantee may not sell, assign, donate, or transfer or otherwise dispose of, mortgage, pledge or encumber Grantee`s rights and interest in the Options, except, in the event of Grantee`s death, to a designated beneficiary, or in the absence of such designation, by will or the laws of descent and distribution or, in the event of Grantee's incapacity, Grantee's guardian or legal representative.  Except as so authorized, no purported assignment or transfer of the Options, or of the rights represented thereby, whether voluntary or involuntary, by operation of law or otherwise (except by will or the laws of descent and distribution), shall vest in the assignee or transferee any interest or right herein whatsoever.  
5.2.         By accepting the Options, Grantee represents and agrees for Grantee and Grantee's transferees (whether by will or the laws of descent and distribution) that: 
(a)           For the period commencing on the Grant Date and ending on the first anniversary of the date upon which Grantee loses status as an Eligible Person (such period is hereinafter referred to as the “Covenant Period”), with respect to any state in which the Company is engaged in business during Grantee's employment with the Company, Grantee shall not participate or engage, directly or indirectly, for Grantee or on behalf of or in conjunction with any person, partnership, corporation or other entity, whether as an employee, agent, officer, director, stockholder, partner, joint venturer, investor or otherwise, in any business activities if such activity consists of any activity undertaken or expressly planned to be undertaken by the Company or any of its subsidiaries or by Grantee at any time during which Grantee maintained status as an Eligible Person.  
(b)           Except with the Company`s prior written approval or as may otherwise be required by law or legal process, Grantee shall not disclose any material or information which is confidential to the Company or its subsidiaries and not in the public domain or generally known in the industry, whether tangible or intangible, made available, disclosed or otherwise known to Grantee as a result of Grantee's status as an Eligible Person.
(c)           During the Covenant Period, Grantee shall not attempt to influence, persuade or induce, or assist any other person in so persuading or inducing, any employee of the Company or its subsidiaries to give up, or to not commence, employment or a business relationship with the Company. 

5.3.         The Company shall have the right, but not the obligation, to purchase and acquire from Grantee any or all of the Shares previously acquired by Grantee upon exercise of an Option (the “Repurchased Shares”) if the Committee reasonably determines that Grantee has violated the covenants set forth in this Agreement or Grantee's loss of status as an Eligible Person is a result of termination of employment for Cause or Grantee's loss of status as an Eligible Person could have resulted from termination of employment for Cause.  The Company may exercise the right granted to it under this Section 5.3 by delivering written notice to Grantee stating that the Company is exercising the repurchase right granted to it under this Section 5.3.  The delivery of such notice by the Company to Grantee shall constitute a binding commitment of the Company to purchase and acquire all of the Repurchased Shares.  The total purchase price for the Repurchased Shares shall be delivered to the Grantee against delivery by Grantee of certificates evidencing the Repurchased Shares no later than thirty days after the delivery of the election notice by the Company.  The price per share of the Repurchased Shares shall be the lesser of 1) the Fair Market Value of each of the Repurchased Shares on the date of the Company`s delivery of its written notice to Grantee or 2) the Option Price.
5.4.         The Company shall have the right, and not the obligation, to cancel any or all of the Options if the Committee reasonably determines that Grantee has violated the covenants set forth in this Agreement.  The Company may exercise the right granted to it under this Section 5.4 by delivering a written notice to Grantee stating that the Company is exercising the cancellation right granted to it under this Section 5.4.
5.5.         Notwithstanding anything in this Section 5 to the contrary, the Company shall not be obligated to purchase any Stock at any time to the extent that the purchase would result in a violation of any law, statute, rule, regulation, order, writ, injunction, decree or judgment promulgated or entered by any Federal, state, local or foreign court or governmental authority applicable to the Company or any of its property.
5.6.         The parties intend the restrictions in Section 5.2 to be completely severable and independent, and any invalidity or unenforceability of any one or more such restrictions shall not render invalid or unenforceable any one or more restrictions.
6.     Exercise; Payment for and Delivery of Shares.  The Options or any portion thereof that is exercisable shall be exercisable for the full amount or for any part thereof. Options which have become exercisable may be exercised by delivery of written notice of exercise to the Committee accompanied by payment of the Option Price.  The Option Price shall be payable in cash and/or shares of Stock valued at the Fair Market Value on the date the Option is exercised or, in the discretion of the Committee, either (i) in other property having a fair market value on the date of exercise equal to the Option Price, or (ii) by delivering to the Committee a copy of irrevocable instructions to a stockbroker to deliver promptly to the Company an amount of sale or loan proceeds sufficient to pay the Option Price.  Payment in currency or by certified or cashier`s check shall be considered payment in cash. Each share of Stock purchased through the exercise of an Option shall be paid for in full at the time of the exercise. 
7.     Stockholder Rights.  Grantee or a transferee of the Options shall have no rights as a stockholder with respect to any Shares covered by the Options until Grantee shall have become the holder of record of such shares (and the Company shall use its reasonable best efforts to cause Grantee to become the holder of record of such shares), and, except as provided in Section 8 of this Agreement, no adjustment shall be made for dividends or distributions or other rights in respect of such Shares for which the record date is prior to the date upon which he or she shall become the holder of record thereof.
8.     Changes in Capital Structure.  The Options shall be subject to adjustment or substitution, as determined by the Committee, as to the number, price or kind of Stock or other consideration subject to such Options or as otherwise determined by the Committee to be equitable (i) in the event of changes in the outstanding Stock or in the capital structure of the Company by reason of stock dividends, stock splits, reverse stock splits, recapitalizations, reorganizations, mergers, consolidations, combinations, exchanges, or other relevant changes in capitalization occurring after the date hereof or (ii) in the event of any change in applicable laws or any change in circumstances which results in or would result in any substantial dilution or enlargement of the rights granted to, or available for, Grantee.  No such adjustment shall be made which would result in an increase in the amount of gain or a decrease in the amount of loss inherent in the Options.  The Company shall give Grantee written notice of an adjustment hereunder.  Notwithstanding anything herein to the contrary, in the event of any of the following:
(a)           The Company is merged or consolidated with another corporation or entity and, in connection therewith, consideration is received by stockholders of the Company in a form other than stock or other equity interests of the surviving entity;
(b)           All or substantially all of the assets of the Company are acquired by another person; or

(c)           The Company`s reorganization or liquidation;

then the Committee may, in its discretion and upon at least ten days advance notice to the affected persons, cancel any outstanding Options and pay to Grantee, in cash, the value of such Options based upon the price per share of Stock received or to be received by other stockholders of the Company in such event and the per share exercise price of the Options.
9.     Requirements of Law.  
9.1.         By accepting the Options, Grantee represents and agrees for Grantee and any transferees (whether by will or the laws of descent and distribution) that, unless a registration statement under the Securities Act of 1933, as amended (the "Securities Act"), is in effect as to the shares purchased upon any exercise of the Options, (i) any and all Shares so purchased shall be acquired for his personal account and not with a view to or for sale in connection with any distribution, and (ii) each notice of the exercise of any portion of this Option shall be accompanied by a representation and warranty in writing, signed by the person entitled to exercise the same, that the shares are being so acquired in good faith for his personal account and not with a view to or for sale in connection with any distribution.
9.2.         No certificate or certificates for Shares may be purchased, issued or transferred if the exercise hereof or the issuance or transfer of such Shares shall constitute a violation by the Company or Grantee of any (i) provision of any Federal, state or other securities law, (ii) requirement of any securities exchange listing agreement to which the Company may be a party, or (iii) other requirement of law or of any regulatory body having jurisdiction over the Company.  Any reasonable determination in this connection by the Company, upon notice given to Grantee, shall be final, binding and conclusive. Notwithstanding any terms or conditions of this Agreement to the contrary, the Company shall be under no obligation to offer to sell or to sell and shall be prohibited from offering to sell or selling any shares of Stock pursuant to the Options unless such shares have been properly registered for sale pursuant to the Securities Act with the Securities and Exchange Commission or unless the Company has received an opinion of counsel, satisfactory to the Company, that such shares may be offered or sold without such registration pursuant to an available exemption therefrom and the terms and conditions of such exemption have been fully complied with. The Company shall be under no obligation to register for sale under the Securities Act any of the shares of Stock to be offered or sold under this Agreement.
9.3.         The certificates representing shares of Stock acquired pursuant to the exercise of Options shall carry such appropriate legend, and such written instructions shall be given to the Company`s transfer agent, as may be deemed necessary or advisable by counsel to the Company in order to comply with the requirements of the Securities Act or any state securities laws.
9.4.         The obligation of the Company to make payment upon the exercise of Options shall be subject to all applicable laws, rules, and regulations, and to such approvals by governmental agencies as may be required.
10.  Taxes.  Grantee understands that Grantee may recognize income for federal and, if applicable, state income tax purposes upon exercise of Options.  Grantee shall be liable for any and all taxes, including withholding taxes, arising out of the grant of the Options or their exercise hereunder.  By accepting the Options, Grantee covenants to report such income in accordance with applicable federal and state laws.  To the extent that the exercise of Options results in income to Grantee and withholding obligations of the Company, including federal or state withholding obligations, Grantee agrees that the obligation shall be satisfied in the manner Grantee has chosen by checking one of the following boxes:
 ̈    At least one working day prior to the exercise date Grantee may deliver to the Company an amount of cash determined by the Company to be adequate to satisfy the Company's withholding obligation.  If Grantee does not deliver such amount of cash, the Company shall withhold an amount of the Grantee's current or future remuneration in an amount that satisfies the Company's withholding obligation.  Notwithstanding the foregoing, the Company may in its sole discretion withhold from the Shares to be issued the specific number of Shares having a fair market value on the vesting date equal to the amount required to satisfy the Company's withholding obligation.
 ̈        The Company shall retain and instruct a registered broker(s) to sell such number of Shares issued upon exercise of Options necessary to satisfy the Company's withholding obligations, after deduction of the broker's commission, and the broker shall remit to the Company the cash necessary in order for the Company to satisfy its withholding obligations.  Grantee covenants to execute any such documents as are requested by the broker of the Company in order to effectuate the sale of the Shares and payment of the tax obligations to the Company.  The Grantee represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Shares.  The Grantee and the Company 

have structured this Agreement to constitute a "binding contract" relating to the sale of Shares pursuant to this Section, consistent with the affirmative defense to liability under Section 10(b) of the Exchange Act under Rule 10b5-1(c) promulgated under the Exchange Act.**     By selecting the second option, Grantee understands that the 
11.  Governing Law; Venue.  
11.1.       The grant of Options and the provisions of this Agreement are governed by, and subject to, the laws of the State of Delaware, without regard to the conflict of law provisions thereof.  
11.2.       For purposes of litigating any dispute that arises under this grant or the Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Tennessee, agree that such litigation shall be conducted in the courts of Shelby County, Tennessee, or the federal courts for the United States for the Western District of Tennessee, where this grant is made and/or to be performed.
12.  Electronic Delivery.  The Company may, in its sole discretion, decide to deliver any documents related to the Options by electronic means and/or administer the Options through electronic means. Grantee hereby consents to receive such documents by electronic delivery and agrees to the administration of the Options through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
13.  Prohibition on Repricing. Without the prior approval of the Company's stockholders, the Company shall not, and the Committee shall not authorize the Company to, (i) amend this Option to reduce its Option Price or (ii) cancel this Option and replace it with the grant of any new equity award with a higher intrinsic value. This prohibition on Option repricing shall not be construed to prohibit the adjustments for extraordinary changes in the Company's capital structure that are otherwise permitted under Section 8 of this Agreement.
14.  Designation and Change of Beneficiary. Grantee may file with the Committee a written designation of one or more persons as the beneficiary who shall be entitled to receive the rights or amounts payable with respect to the Options upon Grantee's death. Grantee may, from time to time, revoke or change Grantee's beneficiary designation without the consent of any prior beneficiary by filing a new designation with the Committee. The last such designation received by the Committee shall be controlling; provided, however, that no designation, or change or revocation thereof, shall be effective unless received by the Committee prior to Grantee's death, and in no event shall it be effective as of a date prior to such receipt. If no beneficiary designation is filed by Grantee, the beneficiary shall be deemed to be Grantee's spouse, if Grantee is unmarried at the time of death, Grantee's estate.
15.  Payments to Persons other than Grantee. If the Committee shall find that any person to whom any amount is payable under this Agreement is unable to care for such person's affairs because of illness or accident, or is a minor, or has died, then any payment due to such person or such person's estate (unless a prior claim therefor has been made by a duly appointed legal representative) may, if the Committee so directs, be paid to such person's spouse, child, relative, an institution maintaining or having custody of such person, or any other person deemed by the Committee to be a proper recipient on behalf of such person otherwise entitled to payment. Any such payment shall be a complete discharge of the liability of the Committee and the Company therefor.
16.  Administration; No Liability of Committee Members. This Agreement shall be administered by the full Board or the Committee. The majority of the members of the Committee shall constitute a quorum. The acts of a majority of the members of the Committee present at any meeting at which a quorum is present or acts approved in writing by a majority of the Committee shall be deemed to be the acts of the Committee. No member of the Committee shall be personally liable by reason of any contract or other instrument executed by such member or on such member's behalf in such member's capacity as a member of the Committee nor for any mistake of judgment made in good faith, and the Company shall indemnify and hold harmless each member of the Committee and each other employee, officer or director of the Company to whom any duty or power relating to the administration or interpretation of this Agreement may be allocated or delegated, against any cost or expense (including counsel fees) or liability (including any sum paid in settlement of a claim) arising out of any act or omission to act in connection with this Agreement unless arising out of such person's own fraud or willful bad faith; provided, however, that approval of the Board shall be required for the payment of any amount in settlement of a claim against any such person. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company's certificate of incorporation or bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.

*    By selecting the second option, Grantee understands that the sale of Shares to satisfy the Company's withholding obligations will be considered a sale for purposes of short-swing liability under Section 16(b) of the Exchange Act.  Any profit realized in a purchase of shares of the Company's stock within six months of the sale may be recovered by the Company or by a stockholder of the Company on behalf of the Company.

17.  Funding. No provision of this Agreement shall require the Company, for the purpose of satisfying any obligations under this Agreement, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes. Grantee shall have no rights under this Agreement other than as an unsecured general creditor of the Company, except that insofar as he may have become entitled to payment of additional compensation by performance of services, he shall have the same rights as other employees under general law.
18.  Reliance on Reports. Each member of the Committee and each member of the Board shall be fully justified in relying, acting or failing to act, and shall not be liable for having so relied, acted or failed to act in good faith, upon any report made by the independent public accountant of the Company and any Related Entity and upon any other information furnished in connection with this Agreement by any person or persons other than himself.
19.  Relationship to Other Benefits. No payment under this Agreement shall be taken into account in determining any benefits under any pension, retirement, profit sharing, group insurance or other benefit plan of the Company except as otherwise specifically provided in such other plan.
20.  Compliance with Section 409A of the Code. 
20.1.       This Agreement shall at all times be administered and the provisions of this Agreement shall be interpreted consistent with the requirements of Section 409A of the Code and any and all regulations thereunder, including such regulations as may be promulgated after the Grant Date. Without limiting the foregoing, for purposes of Section 409A of the Code,
(a)           each “payment” (as defined by Section 409A of the Code) made under this Agreement or the options shall be considered a “separate payment;”
(b)           payments shall be deemed exempt from the definition of deferred compensation under Section 409A of the Code to the fullest extent possible under (i) the “short-term deferral” exemption of Treasury Regulation § 1.409A-1(b)(4), and (ii) with respect to amounts paid as separation pay no later than the second calendar year following the calendar year containing Grantee's “separation from service” (as defined for purposes of Section 409A of the Code) the “two years/two-times” separation pay exemption of Treasury Regulation § 1.409A-1(b)(9)(iii), which are hereby incorporated by reference, and
(c)           if Grantee is a “specified employee” as defined in Section 409A of the Code (and as applied according to procedures of the Company and its affiliates) as of Grantee's separation from service, to the extent any payment under this Agreement or the Options constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A of the Code) and to the extent required by Section 409A of the Code, no payments due under this Agreement or the Options may be made until the earlier of: (i) the first day of the seventh month following Grantee's separation from service, or (ii) Grantee's date of death; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum, without interest, on the first day of the seventh month following Grantee's separation from service. To the extent that the payment terms for the Options are otherwise set forth in a written employment agreement or change in control agreement with a specified employee (or other Company plan applicable to the specified employee) and such payment terms otherwise meet the requirements of Section 409A of the Code and the application of such terms does not result in a violation of Section 409A of the Code, the foregoing payment terms shall be disregarded and the payment terms set forth in the applicable agreement or plan shall apply.  
20.2.       If this Agreement or the Options fail to meet the requirements of Section 409A of the Code, neither the Company nor any of its Affiliates shall have any liability for any tax, penalty or interest imposed on Grantee by Section 409A of the Code, and Grantee shall have no recourse against the Company or any of its Affiliates for payment of any such tax, penalty or interest imposed by Section 409A of the Code.
21.  Miscellaneous.  
21.1.       The Company shall not be required (i) to transfer on its books any shares of Stock of the Company which have been sold or transferred in violation of any provisions set forth in this Agreement, or (ii) to treat as owner of such shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred.

21.2.       The parties agree to execute such further instruments and to take such action as may be reasonably necessary to carry out the intent of this Agreement.
21.3.       Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon delivery to Grantee at the address of Grantee then on file with the Company.  
21.4.       This Agreement shall not, nor shall any provision hereunder, be construed so as to grant Grantee any right to remain associated with the Company or any of its affiliates.
21.5.       The expenses of administering the Agreement shall be borne by the Company.
21.6.       The titles and headings of the sections in the Agreement are for convenience of reference only, and in the event of any conflict, the text of the Agreement, rather than such titles or headings shall control.
21.7.       This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof.

This Agreement and the Options evidenced by this Agreement will not be effective until an original signed Agreement is received by the Wright Medical Group, Inc. Legal Department.  Please print and sign this Agreement immediately, then send the signed Agreement to the Wright Medical Group, Inc. Legal Department as soon as possible.

AGREED AND ACCEPTED

	
		
	GRANTEE:
	WRIGHT MEDICAL GROUP, INC.

	/s/ Pascal E.R. Girin
	By: /s/ James A. Lightman

	Pascal E.R. Girin
	James A. Lightman, SVP. General Counsel & SecretaryWMGI-12.31.2012-10K-Ex 10.53

Exhibit 10.53

SUPPLY AGREEMENT
This Supply Agreement (this “Agreement”), dated as of the 2nd day of November, 2012 (the “Effective Date”), is by and between ORCHID MPS HOLDINGS, LLC, a Delaware limited liability company (“Supplier”), and WRIGHT MEDICAL TECHNOLOGY, INC., a Delaware corporation having a principal place of business at 5677 Airline Road, Arlington, TN 38002 (“Customer”). Supplier and Customer may be referred to herein as a “Party” or, collectively, as the “Parties.”
RECITALS:
WHEREAS, Customer is a designer and seller of orthopedic implants and instrumentation and desires to secure the services and capacity of Supplier; and
WHEREAS, Supplier possesses expertise with regard to the manufacture of orthopedic implants and instrumentation; and
WHEREAS, the Parties desire to enter into this Agreement in accordance with the terms, conditions and provisions contained below.
NOW, THEREFORE, to facilitate these purposes, in consideration of the covenants and obligations expressed herein, the Parties agree to be legally bound as follows:
DEFINITIONS:
Capitalized terms in this Agreement shall have the following meanings:
“Affiliate” shall mean, when used with reference to a Party, any individual or entity directly or indirectly controlling, controlled by or under common control with such Party. For purposes of this definition, “control” means: (a) the direct or indirect ownership of at least 50% of the outstanding voting securities of an entity; (b) the right to control the policy decisions of such entity; or (c) has the power to elect or appoint at least 50% of the members of the board of directors of the entity.
“Applicable Laws” means all applicable laws, ordinances, rules, and regulations of a Governmental Authority, with respect to a Party's performance of its obligations set forth in this Agreement.
“Bankruptcy Event” shall mean the person or entity in question becomes insolvent, or voluntary or involuntary proceedings by or against such person or entity are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such person or entity, or proceedings are instituted by or against such person or entity for corporate reorganization or the dissolution of such person or entity, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or such person or entity makes an assignment for the benefit of its creditors, or substantially all of the assets of such person or entity are seized or attached and not released within sixty (60) days thereafter.
“Confidential Information” shall mean this Agreement, all exhibits attached hereto and all proprietary and confidential information of a Party, including, without limitation, Intellectual Property, trade secrets, technical information, specifications, business and financial information, sales information, customer and potential customer lists and identities, product sales plans, sublicense agreements, inventions, developments, discoveries, software, know-how, methods, techniques, formulae, data, processes and other trade secrets and proprietary ideas, whether or not protectable under patent, trademark, copyright or other areas of law, that the other Party has access to or receives but does not include information that (a) is or becomes publicly available through no fault of the receiving Party, or (b) is received from a Third Party who is under no obligation of confidentiality to the disclosing Party.

1

“FDA” shall mean the United States Department of Health and Human Services Food and Drug Administration or any successor agency.
“Force Majeure Event” shall mean any event beyond the reasonable control of the Party affected by such event and which occurs without the fault or negligence of such Party or any of its subcontractors or suppliers, including, but not limited to, an act of God, failures or delays in transportation, fire, flood, earthquake, storm, war, riot, revolt, act of a public enemy, embargo, explosion, civil commotion, act of terror, or any law, rule, regulation, order by any Governmental Authority.  In each instance, the failure to perform must be beyond the reasonable control of the affected Party.
“Governmental Authority” shall mean any applicable international, domestic federal, state, municipal, local, territorial or other governmental department, regulatory authority, judicial or administrative body.
“Specifications” means the design specifications for Products as provided by Customer to Supplier.
“Intellectual Property” shall mean any and all trade secrets, patents, copyrights, trademarks, service marks, trade names, domain names, trade dress, URLs, brand features, know- how and similar rights of any type under the laws of any applicable Governmental Authority relating to the products manufactured and/or distributed by Customer.
“Product” or “Products” shall mean the products listed on Exhibit A, as such may from time to time be amended by written agreement of the Parties.
“Third Party” shall mean any individual or entity other than a Party or an Affiliate of a Party.
“Work in Process” means (i) partially completed goods, parts, assemblies and/or subassemblies that are no longer part of the raw materials inventory and are not yet a part of the finished products inventory and (ii) the costs of which shall be all costs incurred for work in process to complete firm purchase orders by the Supplier, including, but not limited to, raw materials, machining time, quality assurance and engineering requirements, specialized tooling and outside subcontractors and vendors.
“Vendor Managed Inventory” or “Kan-ban” will be used interchangeably to represent the same process for terms of this Agreement including any written or verbal reference to this contract or program. The VMI or Kan-ban may also be referred to herein as “Program”.  Supplier agrees to work with Customer pursuant to this Agreement to establish an inventory management program based on conditions agreed to by both Supplier and Customer.
ARTICLE 1.
RIGHT TO MANUFACTURE PRODUCTS
1.01     Authorization.  Customer hereby appoints Supplier as its prime vendor to manufacture and supply the Products.  Customer grants Supplier a license to manufacture and supply all of Customer's requirements for the Products, provided that Supplier meets the price, quality, and delivery standards reasonably established by Customer from time to time.  Customer shall discuss with Supplier any new casting programs before selecting any Third Party to manufacture or supply any new casting products.  Customer grants Supplier the right to submit a bid to manufacture and supply any new casting products, which bid shall receive full and good faith consideration from Customer.
ARTICLE 2.
REGULATORY AND MANUFACTURING REQUIREMENTS
2.01     Regulatory Approval. Customer shall be responsible for conducting and paying for all necessary pre-clinical efforts, clinical validation and regulatory obligations related to the Products. Customer will determine the product features and will specify the intended use of the Products. Customer shall be responsible for fulfilling regulatory requirements of 93/42/EEC (Medical 

2

Devices Directive) and all future updates for CE-marking of Products. Customer shall be responsible for any required registration and approval activities for distribution of a Product to international locations where the Products are not already cleared or registered for sale and own all such registrations.
2.02     Specification Developer.  Customer is the specification developer for the Products.  Customer is thereby responsible for (a) establishing, maintaining and following any design control procedures; (b) creating, maintaining and holding all design history files; and (c) obtaining and maintaining any required clearances, approvals, notifications, or market authorizations from the FDA or any other relevant governmental authority.
2.03     Testing Supporting Design Changes.  Testing shall be conducted by Customer, at its expense, to validate and verify any design changes and Customer shall maintain records of design verification and validation test reports.
2.04     Processing.  Supplier will be responsible for manufacturing the Products in accordance with the Specifications. Supplier shall maintain production records and storage records, if applicable, and shall make said records available for Customer as reasonably requested and shall retain those records in accordance with the requirements of Applicable Laws.  Customer will provide the molds necessary to produce the Products.  Upon expiration or termination of this Agreement, Supplier will promptly return to Customer any and all molds provided by Customer to Supplier.  For the avoidance of doubt, the molds provided hereunder at all times shall remain the sole and exclusive property of the Customer. Supplier acknowledges and agrees that the molds provided hereunder are to be solely and exclusively use in the production of the Products for Customer.  
2.05      Notification of Significant Changes.  Supplier shall provide thirty (30) days prior written notice of, and obtain Customer's approval, which shall not be unreasonably withheld, about any changes to Supplier's manufacturing processes. “Changes” are those that will impact the quality, safety, regulatory status of Products and include changes in the composition or method of processing or as required by applicable standards or regulations.
2.06     Products Complaints.  Customer will be the designated Party to receive complaints and promptly advise Supplier, in writing, of complaints attributable to the Products manufactured by Supplier under the terms contained in this Agreement. Supplier and Customer will maintain product complaint files, including related investigations.
2.07     Investigations.  Supplier will conduct product complaint investigations related to the manufacture or processing of Products upon request from Customer. Supplier will provide reasonable assistance in complaint investigations and will provide any information available to Supplier to close those investigations. Supplier agrees to provide the results of its investigations to Customer within thirty (30) days of receiving the complaint and to provide ongoing updates to Customer as requested.
2.08     Reports to FDA.  Each party will comply with applicable FDA reporting requirements with respect to adverse events or corrections and removals.
2.09     Registrations and Licenses.  Supplier shall maintain its current registrations and licenses as required by Customer pursuant to its vendor qualification requirements.
2.10     Compliance with Law.  The Parties shall at all times conduct themselves and all activities performed under this Agreement in full compliance with all Applicable Laws, as amended from time to time.
ARTICLE 3.
PROCESSING, SUPPLY, AND DISTRIBUTION
3.01     Contact Person.  As soon as reasonably practicable after the Effective Date, each Party shall identify, by written notice, a contact person to serve as the primary liaison between the 

3

Parties with regard to manufacture and supply issues. Each Party may replace its contact person, at any time, upon written notice identifying the new contact person.
3.02     Specifications.  Supplier agrees to manufacture and supply Products to Customer in accordance with the Specifications and the requirements provided by Customer, which shall be consistent with the requirements and Specifications in effect with respect to the casting operation of Customer as it existed immediately before the execution of this Agreement.  Supplier shall supply the Products with a certification that the Products meet Customer's Specifications.  Non-conforming Products may, at Customer's option, be returned for credit or replacement at Supplier's expense.  All Products delivered pursuant to this Agreement shall be free and clear of all claims, encumbrances, liens and security interests.
3.03     Quality obligation.  Supplier will maintain a quality system that satisfies Customer's vendor qualification process, and be good manufacturing practice compliant in accordance with appropriate FDA 21CFR Part 820 guidelines as currently in effect as of the date hereof, as verified by Customer personnel, and subject to periodic Customer audit. In the event that these regulations are modified, amended or otherwise updated, Supplier will modify, amend or otherwise update and maintain a quality system in accordance therewith. Customer acknowledges that Supplier's current quality system satisfies Customer's vendor qualification process.
3.04     Regulatory.  Supplier shall notify Customer within ten (10) days of all inspections by FDA or any other applicable regulatory authorities whether domestic or outside U.S. territories or its borders.  Inspections include but are not limited to planned, unplanned or electronic communication or any investigation where Supplier's is contacted related to facility, products, processes, materials or personnel associated with the production of any of Customer products or processes or any and all equipment used by Supplier. Supplier agrees to allow Customer to participate in the investigation or inspection with respect to Products. Except as it relates to proprietary Customer-specific information, the Parties shall provide each other the full results of the inspection, and any responses thereto, that are related to said products or investigation.
3.05     Record Keeping.  Supplier shall, for as long as required by Applicable Law, keep complete records and books covering the manufacture of Products including details of component and raw material procurement and other documents relating to this Agreement.  Supplier agrees to permit Customer, at Customer's expense upon reasonable request and during ordinary business hours, and to have access to and make copies of such records, books and all other documents and materials in the possession and under the control of Supplier directly relating to or pertaining to the Products.  Customer shall provide Supplier at least thirty (30) days prior written notice of a record inspection requested pursuant to this paragraph, and Customer shall be entitled to no more than one record inspection in any six-month period.
3.06     Regulatory Inspection.  Following inspections by applicable regulatory authorities, including, without limitation, the FDA or applicable regulatory authorities of products or processes as identified in Section 3.04, Supplier shall do such actions or cause such actions to be done that are necessary, advisable or appropriate so that Supplier remains in good standing with any such regulatory authorities.
3.07     Order, Acceptance and Supply of the Product.  All orders for Products shall be filled by Supplier based upon the conditions as stated below:
(a)With respect to each Product, Customer will issue to Supplier blanket and/or firm orders for a period of one full calendar quarter, and provide any available information or forecasts covering a period of three additional calendar quarters. Six (6) weeks prior to the beginning of the forecast quarter, Customer will issue to Supplier a blanket and/or firm purchase order for the next calendar quarter period of forecast, and will make available a forecast for the next three (3) 

4

calendar quarters. Supplier will supply Products in accordance with such orders and the Specifications or other Products in accordance with agreed and acknowledged purchase orders.  Supplier will use commercially reasonable efforts to meet Customer's delivery requirements.
(b)In the event Supplier is unable to manufacture Products in accordance with the Specifications and in such quantities specified in Customer purchase orders and forecasts for any reason, except for a default by Customer hereunder or a Force Majeure Event, then Supplier shall have the obligation to retain a subcontractor to manufacture the Products in accordance with the Specifications.  The subcontractor must be a qualified alternative manufacturer and meet or exceed Customer quality standards through the remaining terms and conditions contained in this Agreement; Products manufactured by a subcontractor shall be supplied to Customer at no additional cost.  To the extent Supplier cannot or does not engage a subcontractor to manufacture the Products in accordance with the Specifications and in such quantities set forth in Customer purchase orders and forecasts, Customer has the right to retain a Third Party to manufacture the Products, and Supplier shall reimburse Customer for incremental costs incurred by Customer in the manufacture or delivery of the Product in an amount up to 50% above Supplier's price for supplying such Product hereunder.  For the avoidance of doubt, Supplier will not be liable for any Third Party costs incurred by Customer to manufacture and deliver Product in the event of (i) a default by Customer hereunder, (ii) a Force Majeure Event or (iii) Customer requests for Product in excess of purchase orders and forecasts.
3.08     Delivery Terms.  Unless directed in writing by Customer to the contrary, all deliveries of Products by Supplier to Customer shall be delivered to Customer's facility in Arlington, TN. All shipments will be FOB Supplier's facility, at which point title shall pass to Customer, and Supplier's liability as to delivery shall cease.  Supplier has no responsibility for risk of damage to or loss or delay of Products if package in accordance with Customer's requirements.  Supplier will pay freight from Supplier's facility in Oregon City, Oregon to Customer's facility in Arlington, TN based on normal course of business freight shipments.  Special or unusual requirements placed by Customer for expedited shipments shall be negotiated at the time shipment is required. 
3.09     Packaging.  Supplier shall package and label Products according to the Specifications provided by Customer and as noted on a purchase order and shall be included as part of the invoice prices described in Section 4.01.
3.10     Inspection of Shipment and Notice of Claims.  Customer must inspect delivered Products within a reasonable time of delivery, and Customer shall notify Supplier in writing of any shortage of products or non-conforming Products within thirty (30) days of its receipt of the shipment of Products from Supplier.  Products are non-conforming if they do not satisfy the requirements set forth in the Specifications or the applicable purchase order.  If Customer does not notify Supplier in writing of any shortage of Products or non-conforming Products within thirty (30) days of its receipt of shipment, the Products shall be deemed accepted by Customer.  In the case of non-conformance due to latent defects or other defects which are not readily observable, if Customer fails to notify Supplier in writing of the non-conforming Products within the thirty (30) days after Customer knows, or should have known of the defects, the Products shall be deemed accepted by Customer.
3.11     Reservation of Rights.  Except as expressly provided in this Agreement, no right, title or interest is granted, whether express or implied, by Customer to Supplier, and nothing in this Agreement shall be deemed to restrict Customer's right to exploit Customer's own Intellectual Property relating to Products provided that such exploitation does not use Intellectual Property of Supplier. Notwithstanding the above, any patentable or unpatentable inventions, discoveries, improvements, processes, methodologies, and ideas of general applicability relating to Products except those that directly relate to Supplier processes shall be the sole property of Customer.

5

3.12     Customer Marks/Marketing.  Supplier acknowledges that Customer is the sole and exclusive owner of its trademarks, service marks, insignias, and copyrighted materials, and Supplier will not claim rights of ownership therein or make any attempt to register them nor will they reference or display Customer name or products without prior written permission of Customer.
ARTICLE 4.
COMPENSATION TERMS
4.01      Pricing/Supply Costs for Products.  The price of the Products is set forth on Exhibit A. Prices for the Products shall be adjusted at least annually to reflect raw material cost fluctuations.  On each anniversary of the Effective Date, and/or at such other times as the Parties may mutually determine, the Parties shall negotiate in good faith to adjustments to prices for Products based on Supplier's raw material costs and in accordance with the methodology set forth on Exhibit B.  Supplier will reserve raw materials to cover expected demand for the forecast period agreed upon by the Parties, which shall not exceed one year.  The prices listed on Exhibit A as of the Effective Date reflect a cost of Co of $[***] per pound, Mo of $[***] per pound, and Cr of $[***] per pound.
4.02     Payment Terms.  Payment terms will be net forty-five (45) days from the date of the invoice of Products shipped by Supplier in acceptable condition.
4.03     Taxes.  All payments required to be made by Customer to Supplier, under this Agreement are exclusive of any applicable federal, state and local taxes. Any present or future sales, revenue, excise, withholding or other tax, fees, or charge of any nature, imposed by any public authority, applicable to the purchase of Products hereunder (other than value added taxes or taxes based on Supplier's net income), shall be added to the purchase price and shall be paid by Customer unless an exemption therefrom is obtained.
4.04     Minimums.  Customer is not required to purchase any minimum amount of Products.
4.05     VMI and/or Kan-Ban Process.  In an effort to smooth out production Supplier agrees to implement a VMI and/or Kan-ban process. Supplier and Customer will work together to develop mutually beneficial stock levels and order quantities that help both companies reduce inventory and maintain steady production flow.
ARTICLE 5.
TERM AND TERMINATION
5.01     Term and Renewal.  This Agreement shall begin on the Effective Date and shall continue for ten (10) years unless terminated earlier in accordance with this Article 5
5.02     Termination.  Either Party may terminate this Agreement immediately upon written notice to the other Party in the event:
(a)    The other Party becomes the subject of a Bankruptcy Event which is not dismissed within sixty (60) days of the filing of the bankruptcy petition; or
(b)    With cause upon thirty (30) days' advance written notice after a material breach or material default by the other Party of any provision of this Agreement occurs, and such Party fails to remedy such breach or default if notified in writing. The thirty (30) day time period shall be automatically extended provided the defaulting Party is exercising diligence to remedy the breach or default and diligently continues to remedy the breach or default.
5.03     Termination without Cause. Either Customer or Supplier may terminate this Agreement without cause and without any liability for either party except as specifically provided in Section 5.04 by providing at least one (1) year prior written notice to the other Party.
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

6

5.04     Upon Termination.  Upon termination of this Agreement, this Agreement shall thereafter have no effect, except that:
(a)     the provisions of Articles 5, 6, 7, and 9 shall survive and apply,
(b)     payment obligations that have accrued prior to the date of termination shall remain due and payable in accordance with the terms of this Agreement,
(c)payment obligations that have accrued but have not been invoiced as of the date of termination shall be invoiced and paid in full within thirty (30) days of receipt of such invoice,
(d)Supplier shall fill all firm orders in effect at the time of the termination unless otherwise agreed by the Parties,
(e)Supplier shall promptly return to Customer any and all molds provided by Customer to Supplier,
(f)the Parties shall return to each other all information, data and material furnished to the other Party and designated as Confidential together with all copies thereof,
(g)neither Party shall be relieved from liability for any breach of any representation, warranty or agreement hereunder occurring prior to such termination, and
(h)all remaining inventory, purchase orders, and work in process, not in excess of the purchase orders, and all raw materials not in excess of the agreed-upon forecast period under Section 4.01, held by Supplier or being or to be completed by Supplier shall be scheduled for delivery and the costs thereof shall be invoiced to Customer and will become due and payable; provided that Supplier uses commercially reasonable efforts to mitigate any damages suffered from holding such excess inventory, work in process, and raw materials.
ARTICLE 6.
CONFIDENTIALITY
6.01     Confidentiality Obligations.  Except as permitted elsewhere under the terms of this Agreement, each Party shall:
(a)     receive and maintain the Confidential Information of the other Party in strict confidence;
(b)     not disclose such Confidential Information to any Third Parties unless expressly needed for product development or manufacturing and as agreed in writing by the Parties; and
(c)    promptly notify the disclosing Party upon learning of any Applicable Law, rule, regulation or court order that purports to compel disclosure of any Confidential Information of the disclosing Party and to reasonably cooperate with the disclosing Party in the exercise of the disclosing Party's right to protect the confidentiality of such Confidential Information.
Neither Party hereto shall use all or any part of the Confidential Information of the other Party for any purpose other than to perform its obligations under this Agreement. Each Party shall ensure that its employees, representatives and agents comply with this provision.
6.02     Exclusions.  Nothing contained herein shall prevent a Party from disclosing Confidential Information pursuant to any Applicable Law or to any subcontractor who needs to know such information for the purposes of this Agreement so long as such subcontractor agrees to be bound by the terms of the confidentiality provisions contained herein; provided that such Party complies with the notice provisions of Section 6.01(c) to the extent permissible under Applicable Law.  

7

Such disclosure shall not alter the status of such information hereunder for all other purposes as Confidential Information.
6.03     Termination. Upon termination of this Agreement, all Confidential Information shall be returned to the disclosing Party or destroyed, unless otherwise specified or permitted elsewhere under this Agreement. Trade secret information shall remain confidential so long as it meets the definition of Confidential Information.
6.04     Injunction.  Each Party acknowledges and agrees that the provisions of this Article 6 are reasonable and necessary to protect the other Party's interests in its Confidential Information, that any breach of the provisions of this Article 6 may result in irreparable harm to such other Party and that the remedy at law for such breach may be inadequate. Accordingly, in the event of any breach or threatened breach of the provisions of this Article 6 by a Party hereto, the other Party, in addition to any other relief available to it at law, in equity or otherwise, shall be entitled to seek temporary and permanent injunctive relief restraining the breaching Party from engaging in or continuing any conduct that would constitute a breach of this Article 6, without the necessity of proving actual damages or posting a bond or other security.
6.05     Publicity.  Except as may be required by Applicable Laws (including those arising under any securities laws), neither Party will originate any publicity, news release or other public announcement, written or oral, whether to the public press or otherwise, concerning the relationship between the Parties or the transactions described in this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. In the event disclosure is required by Applicable Law, then the Party required to so disclose such information shall, to the extent possible, provide to the other Party for its approval (such approval not to be unreasonably withheld) a written copy of such public announcement at least five (5) business days prior to disclosure.
ARTICLE 7.
REPRESENTATIONS AND WARRANTIES, INDEMNIFICATION, 
LIMITATION ON DAMAGES AND INSURANCE
7.01     Mutual.  Each Party hereby represents, covenants and warrants to the other Party that:
(a)     It has the corporate power, or limited liability company power, as applicable, to enter into this Agreement and to grant the rights and licenses granted herein and otherwise perform this Agreement;
(b)    to the best of each Party's knowledge, the entering into of this Agreement by such Party will not (i) violate any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body or (ii) conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default under its organizational documents, as amended to date, or any material note, indenture, mortgage, lease, agreement, contract, purchase order or other instrument, document or agreement;
(c)    When executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in accordance with the provisions of this Agreement; and
(d)    it shall perform its obligations under this Agreement in compliance with all Applicable Laws.
7.02     Products.  Supplier represents and warrants to the best of its knowledge that the Products delivered to Customer shall be in accordance with this Agreement and will not deviate from the Specifications and that any damage arising from Supplier's breach of this warranty shall promptly be remedied by Supplier at its sole expense.  EXCEPT FOR THE LIMITED EXPRESS WARRANTIES 

8

CONTAINED IN THIS AGREEMENT, SUPPLIER DOES NOT MAKE ANY WARRANTIES, EXPRESS OR IMPLIED, IN FACT OR IN LAW, WITH RESPECT TO ANY PRODUCT OR SERVICES PROVIDED HEREUNDER, INCLUDING, BUT NOT LMITED TO, ANY IMPLIED WARRANTIES OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PERFORMANCE OR NONINFRINGEMENT.  EXCEPT FOR THE LIMITED EXPRESS WARRANTIES CONTAINED IN THIS AGREEMENT, ALL SUCH OTHER WARRANTIES ARE HEREBY DISCLAIMED.
7.03     Design Services.  Customer expressly acknowledges that it is solely responsible for all aspects of the design of the Products and that Supplier has no responsibility and makes no representations or warranties whatsoever regarding the design of the Products.  Customer warrants to Supplier that its design work and resulting Specifications represent original work product and do not directly or indirectly infringe upon the intellectual property rights of any Third Party.
7.04     Indemnification by Customer.  Customer shall, indemnify and hold harmless Supplier, its Affiliates and their respective officers, directors, employees and agents from and against any and all losses, damages, liabilities, obligations, penalties, judgments, awards, costs, expenses, including reasonable attorney and court costs, and disbursements, including without limitation, the costs, expenses and disbursements, as and when incurred, of investigating, preparing or defending any claim, action, suit, proceeding or investigation asserted by a Third Party, caused by, relating to, based upon, arising out of or in connection with (a) (i) negligence, (ii) defect in the design of the Products, or (iii) recklessness or intentional misconduct or misstatements, on the part of Customer or its Affiliates or any of their officers, directors or employees, or (b) Customer's breach of any duty, representation warranty or covenant of this Agreement or (c) any claim that Customer's processes or Customer's designed products infringe intellectual property rights of any Third Party or (d) any claim against Supplier resulting from the use or misuse of the Products.
7.05     Indemnification by Supplier.  Supplier shall indemnify and hold harmless Customer, its Affiliates and their respective officers, directors, employees and agents from and against any and all losses, damages, liabilities, obligations, penalties, judgments, awards, costs, expenses, including reasonable attorney and court costs, and disbursements, including without limitation, the costs, expenses and disbursements, as and when incurred, of investigating, preparing or defending any claim, action, suit, proceeding or investigation asserted by a Third Party, caused by, relating to, based upon, arising out of or in connection with (a) (i) negligence, (ii) defect arising out of the manufacture of the Products, or (iii) recklessness or intentional misconduct or misstatement, on the part of Supplier, its Affiliates or any of their officers, directors or employees, or (b) Supplier's breach of any duty, representation warranty or covenant of this Agreement.
7.06    Indemnitee Obligations.  Each person seeking to be reimbursed, indemnified, or held harmless (each, an “Indemnitee”) shall
(a)    provide the Party obliged to indemnify such Indemnitee with prompt written notice of any claim, suit, demand or other action for which such Indemnitee seeks to be reimbursed, indemnified, or held harmless (each, a “Claim”), which notice shall include a reasonable identification of the alleged facts giving rise to such Claim,
(b)    grant such Party reasonable input regarding any such Claim and
(c)    reasonably cooperate with such Party and its agents in defense of any such Claim at the indemnifying Party's expense.
Each Indemnitee shall have the right to participate in the defense of any Claim for which such Indemnitee seeks to be reimbursed, indemnified, or held harmless, by using attorneys of such Indemnitee's choice, at such Indemnitee's expense. Any settlement of a Claim for which any Indemnitee seeks to be reimbursed, indemnified, or held harmless under this Article 7 shall be

9

subject to the prior written approval of such Indemnitee, such approval not to be unreasonably withheld, conditioned or delayed.
7.07     Essential Part of Bargain.  The Parties acknowledge that the provisions set forth in this Article 7 are an essential element of this Agreement between the Parties and that the Parties would not have entered into this Agreement without such provisions.
7.08     Adequate Insurance.  During the term of this Agreement, each of the Parties shall obtain and maintain at its sole cost and expense, product liability insurance or self-insurance that meets the following requirements (a) the insurance shall insure such Party and its Affiliates against all liability related to the product, including liability for bodily injury, property damage, wrongful death and any contractual indemnity obligations imposed by this Agreement, and (b) the insurance shall be in amounts, respectively, that are reasonable and customary in the industry for companies of comparable size and activity but in no event less than One Million and 00/100 Dollars per claim and Five Million Dollars in the aggregate. The Parties shall provide each other with a certificate of insurance evidencing the above coverage prior to commencing any work under this Agreement. The insurance certificate to be furnished must also evidence, that the Party's policies of insurance, which are required hereunder, have been endorsed to (x) provide the other Party with thirty (30) days' prior written notice of cancellation of such insurance coverage for any reason, except for non-payment of premium, as to which the other Party shall receive ten (10) days' prior written notice of cancellation, (y) name the certificate holder, its affiliates, subsidiaries, officers, directors, and employees (collectively, the “Certificate Holder”) as additional insureds, and (z) waive subrogation against the Certificate Holder. If a Party carries umbrella liability coverage, then, all of the requirements of this paragraph shall apply to such umbrella liability coverage. Notwithstanding the foregoing, coverage for a Certificate Holder as an additional insured will not apply to bodily injury, property damage or any other damages arising out of the negligent or willful acts or omissions of Certificate Holder, any employees of Certificate Holder or any third party.
7.09     Limitation on Damages.  NOTWITHSTANDING ANY OTHER TERM OF THIS AGREEMENT, IN NO EVENT SHALL ANY PARTY, OR SUCH PARTY'S DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES, BE LIABLE TO THE OTHER PARTY HERETO FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES, COSTS OR EXPENSES (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOST REVENUES AND/OR LOST SAVINGS), WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, ARISING FROM A BREACH OR ALLEGED BREACH OF THIS AGREEMENT OR THE USE OF ANY PRODUCT SUPPLIED TO CUSTOMER HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.
ARTICLE 8.
FORCE MAJEURE
8.01     Performance Delay.  The performance of a Party impacted by a Force Majeure Event, other than the satisfaction of payment obligations that have accrued under this Agreement, is delayed, without liability, for the duration of a Force Majeure Event.
8.02     Notice.  The Party whose performance is affected by a Force Majeure Event (the “Affected Party”) shall give prompt written notice to the other Party stating the details and expected duration of the event. Once notice is given of a Force Majeure Event, the Parties shall keep each other reasonably informed of the situation until the Force Majeure Event terminates or this Agreement is terminated, whichever occurs first. If the performance of the Affected Party does not resume within twelve (12) months of the occurrence of a Force Majeure Event, the other Party shall have the right to terminate this Agreement without penalty, except Customer's satisfaction of payment obligations that have accrued under this Agreement shall survive the termination of this Agreement. Each Party has full management discretion in dealing with its own labor issues.

10

ARTICLE 9.
MISCELLANEOUS
9.01     Governing Law.  This Agreement shall be governed by and interpreted under the laws of the State of Tennessee, without regard to its conflicts of law provisions. Further, the United Nations Convention on Contracts for the International Sale of Goods, 1980, shall not apply hereto. Any action, litigation, claim, dispute, or proceeding relating in any way, either directly or indirectly, to this Agreement shall be brought exclusively in the state courts of Shelby County, Tennessee, or the U.S. District Court for the Western District of Tennessee, as applicable. Both Parties consent to the jurisdiction and venue of the courts referenced herein and agree not to assert the defense of forum non-conveniens.
9.02     No Assignment.  Supplier may not transfer or assign any rights or delegate any obligations hereunder, in whole or in part, whether voluntarily or by operation of law, without the prior written consent of Customer, which consent may be withheld pursuant to reasonable business discretion.  Customer may freely assign its rights hereunder.  Subject to the foregoing, all of the terms, conditions and provisions of this Agreement shall be binding upon and shall inure to the benefit of the permitted successors and assigns of the respective parties hereto.
9.03     Independent Contractors.  In connection with this Agreement, each Party is an independent contractor. This Agreement does not, and shall not be construed to, create an employer-employee, agency, joint venture or partnership relationship between the Parties. Neither Party shall have any authority to act for or to bind the other Party in any way, to alter any of the terms or conditions of any of the other Party's standard forms of invoices, sales agreements, warranties or otherwise, or to warrant or to execute agreements on behalf of the other or to represent that it is in any way responsible for the acts, debts, liabilities or omissions of the other Party.
9.04. Notices.  All notices, reports, payments and other communications required or permitted to be given under this Agreement (each, a “Notice”) shall be in writing and shall be given either by personal delivery against a signed receipt, by express delivery using a nationally recognized overnight courier or by facsimile. All Notices shall be properly addressed as follows, or to such other addresses as may be specified in a Notice given hereunder:
	
			
	If to Supplier:
	 
	with a copy to:

	Matt Burba
	 
	Jorge M. Ramos

	Executive VP of Implant Mfg
	 
	Chief Financial Officer

	1489 Cedar St.
	 
	1489 Cedar St.

	Holt, MI 48842
	 
	Holt, MI 48842

	Facsimile: (517) 694-2340
	 
	Facsimile: (517) 694-2340

	 
	 
	 

	If to Customer:

	 
	with a copy to:

	Director of Procurement
	 
	General Counsel

	Wright Medical Technology, Inc.
	 
	Wright Medical Technology, Inc.

	5677 Airline Road
	 
	5677 Airline Road

	Arlington, TN 38002
	 
	Arlington, TN 38002

	Facsimile: (901) 867-9534
	 
	Facsimile: (901) 867-9534

A Notice shall be deemed to be effective upon personal delivery or, if sent via overnight delivery, upon receipt thereof. A Notice sent via facsimile is deemed effective on the same day (or if such day is not a business day, then on the next succeeding business day) if such facsimile is sent before 5:00 p.m. Central Standard Time and on the next day (or if such day is not a business day, then on the next succeeding business day) if such Notice is sent after 5:00 p.m. Central Standard Time.
9.05     Amendment or Modification.  No subsequent amendment, modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the Parties.

11

9.06     Entire Agreement.  This Agreement and the exhibits attached hereto set out the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements, proposals, arrangements and communications, whether oral or written, with respect to the subject matter hereof.  In the event that there is a conflict between the terms contained in the Exhibits and the terms contained in this Agreement, then except for the terms contained in Exhibit A, this Agreement shall control. The terms contained in Exhibit A shall control the terms contained in the Agreement.
9.07     Severability.  If any provision of this Agreement is held by a tribunal of competent jurisdiction to be illegal, invalid or otherwise unenforceable in any jurisdiction, then to the fullest extent permitted by law (a) the same shall not effect the other provisions of this Agreement, (b) such provision shall be deemed modified to the extent necessary in the tribunal's opinion to render such provision enforceable, and the rights and obligations of the Parties shall be construed and enforced accordingly, preserving to the fullest extent the intent and agreements of the Parties set forth herein and (c) such finding of invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.
9.08     No Waiver.  Failure to enforce any term of this Agreement is not a waiver of future enforcement of that or any other term. No term or provision of this Agreement will be deemed waived and no breach excused unless such waiver or excuse is in writing and signed by the Party against whom enforcement of such waiver or excuse is sought.
9.09     No Third Party Beneficiaries.  Nothing in this Agreement is intended to confer benefits, rights or remedies unto any person or entity other than the Parties and their permitted successors and assigns.
9.09     Headings.  The headings appearing at the beginning of the sections contained in this Agreement have been inserted for identification and reference purposes only and shall not be used to determine the construction or interpretation of this Agreement. The nomenclature of the defined terms in this Agreement shall only be used for the construction of this Agreement and are not to be used for any other purpose, including, but not limited to, interpretation for accounting purposes.
9.10     Execution in Counterparts, Facsimiles.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, bear the signatures of both Parties hereto. For the purposes hereof, a facsimile copy of this Agreement, including the signature pages hereto, shall be deemed an original.
9.11    Controlling Agreement.  In the event any term of this Agreement is inconsistent with the terms of a purchase order issued by Customer or purchase order acknowledgment issued by the Supplier, then the terms of this Agreement shall control.

[SIGNATURE PAGE AND EXHIBITS TO FOLLOW.]

12

IN WITNESS WHEREOF, the Parties to the Agreement by their duly authorized representatives have executed this Agreement as of the date first written above.
	
		
	ORCHID MPS HOLDINGS, LLC
	WRIGHT MEDICAL TECHNOLOGY, INC.

	 
	 

	By:/s/ Michael E. Miller
	By:/s/ William L. Griffin

	Name:  Michael E. Miller
	Name:  William L. Griffin

	Title:Chief Executive Officer
	Title:Senior Vice President, Global Operations

13

EXHIBIT A
PRODUCTS
	
							
	2011 Foundry Completions 
	 
	 
	 
	 
	 

	9/27/2012
	 
	 
	 
	 
	 
	 

	Part #
	Item Description
	Do Ty
	G/L Cat
	Or Ty
	 ABP
	Price

	106303
	IMP FEM PC SM+ RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106304
	IMP FEM PC MD LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106305
	IMP FEM PC MD RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106307
	IMP FEM PC LG RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106308
	IMP FEM PC LG+ LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106310
	IMP FEM PC XLG LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106311
	IMP FEM PC XLG RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	106386
	IMP FEM LG RT KNE CC WT3C
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	107890
	IMP FEM POST STAB XLG LT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	108456
	IMP FEM PC MD+ LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	108457
	IMP FEM PC MD+ RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	111086
	IMP FEM POST STAB NON POR OPEN
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	111641
	IMP TIB MD+ KNE CC OADV C
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	117240
	IMP HIP HEMI 36-37 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117244
	IMP HIP HEMI 44-45 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117245
	IMP HIP HEMI 46-47 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117246
	IMP HIP HEMI 48-49 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117247
	IMP HIP HEMI 50-51 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117248
	IMP HIP HEMI 52-53-54 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	117249
	IMP HIP HEMI 55-56-57 CAST CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118339
	IMP INSERT 28/37 F75 GI
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118340
	IMP INSERT 28/41 F75 GII
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118341
	IMP INSERT 28/48 F75 GIII
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118342
	IMP INSERT 28/52 F75 GIV
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118343
	IMP INSERT 32/41 F75 GII
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118344
	IMP INSERT 32/48 F75 GIII
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118525
	IMP 28MM HEAD F-75 CAST
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118526
	IMP 32MM HEAD F-75 CAST
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	118527
	IMP 36MM HEAD F-75 CAST
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	123941
	IMP BASE SZ 1 KNE CC ADV CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	123942
	IMP BASE SZ 2/1+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	123943
	IMP BASE SZ 3/2+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-1
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	123944
	IMP BASE SZ 4/3+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	123945
	IMP BASE SZ 5/4+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	123946
	IMP BASE SZ 6/5+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	124994
	IMP HIP HEMI 38-42 CC F75
	IC
	CM14
	WO
	 $    [***]
	 $    [***]

	125149
	IMP PCR FEM RT SIZE 0
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	125974
	IMP TIB.HNGE.BASE SLM.STM
	IC
	CM14
	WO
	 $    [***]
	 $    [***]

	127448
	IMP FEM KNE LT 72MM RSCTN
	IC
	CM14
	WO
	 $    [***]
	 $    [***]

	127449
	IMP FEM KNE RT 72MM RSCTN
	IC
	CM14
	WO
	 $    [***]
	 $    [***]

	128820
	IMP CUP SZ.AA HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	128821
	IMP CUP SZ.A HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	128822
	IMP CUP SZ.B HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	128823
	IMP CUP SZ.C HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	128824
	IMP CUP SZ.D HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129140
	IMP CAST TIB SZ 2.5 CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	129752
	IMP SPIKED CUP 40 X 46
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129753
	IMP SPIKED CUP 42 X 48
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129754
	IMP SPIKED CUP 44 X 50
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129755
	IMP SPIKED CUP 46 X 52
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129756
	IMP SPIKED CUP 48 X 54
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129757
	IMP SPIKED CUP 50 X 56
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129758
	IMP SPIKED CUP 52 X 58
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129759
	IMP SPIKED CUP 54 X 60
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129905
	IMP CUP CAST 36 X 42 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129909
	IMP CUP CAST 44 X 50 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129910
	IMP CUP CAST 46 X 52 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129911
	IMP CUP CAST 48 X 54 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129912
	IMP CUP CAST 50 X 56 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129913
	IMP CUP CAST 52 X 58 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129914
	IMP CUP CAST 54 X 60 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	129915
	IMP CUP CAST 56 X 62 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	130496
	IMP CAST SZ 1 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130497
	IMP CAST SZ 1 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130498
	IMP CAST SZ 2 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130499
	IMP CAST SZ 2 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130500
	IMP CAST SZ 3 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130501
	IMP CAST SZ 3 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130502
	IMP CAST SZ 4 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130503
	IMP CAST SZ 4 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-2
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	130504
	IMP CAST SZ 5 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130505
	IMP CAST SZ 5 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130507
	IMP CAST SZ 6 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130508
	IMP CAST SZ 1 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130509
	IMP CAST SZ 1 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130510
	IMP CAST SZ 2 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130511
	IMP CAST SZ 2 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130512
	IMP CAST SZ 3 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130513
	IMP CAST SZ 3 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130514
	IMP CAST SZ 4 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130515
	IMP CAST SZ 4 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130516
	IMP CAST SZ 5 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130517
	IMP CAST SZ 5 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130538
	IMP CAST SZ 1 FEM POST STAB NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130539
	IMP CAST SZ 2 FEM POST STAB NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130540
	IMP CAST SZ 3 FEM POST STAB NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130541
	IMP CAST SZ 4 FEM POST STAB NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130542
	IMP CAST SZ 5 FEM POST STAB NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130544
	IMP CAST SZ 1 FEM LT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130545
	IMP CAST SZ 1 FEM RT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130546
	IMP CAST SZ 2 FEM LT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130547
	IMP CAST SZ 2 FEM RT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130548
	IMP CAST SZ 3 FEM LT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130549
	IMP CAST SZ 3 FEM RT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130550
	IMP CAST SZ 4 FEM LT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130551
	IMP CAST SZ 4 FEM RT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130552
	IMP CAST SZ 5 FEM LT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130553
	IMP CAST SZ 5 FEM RT REV NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130556
	IMP CAST SZ 1.5 FEM LT PRIM NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130557
	IMP CAST SZ 1.5 FEM RT PRIM NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130558
	IMP CAST SZ 1.5 FEM LT PRIM PC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130559
	IMP CAST SZ 1.5 FEM RT PRIM PC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130569
	IMP CAST SZ 4 FEM LT MD/RT LAT
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130577
	IMP CAST SZ 1 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130578
	IMP CAST SZ 1 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130579
	IMP CAST SZ 2 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130580
	IMP CAST SZ 2 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130581
	IMP CAST SZ 3 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-3
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	130582
	IMP CAST SZ 3 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130583
	IMP CAST SZ 4 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130584
	IMP CAST SZ 4 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130585
	IMP CAST SZ 5 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130586
	IMP CAST SZ 5 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130587
	IMP CAST SZ 1 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130588
	IMP CAST SZ 1 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130589
	IMP CAST SZ 2 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130590
	IMP CAST SZ 2 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130591
	IMP CAST SZ 3 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130592
	IMP CAST SZ 3 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130593
	IMP CAST SZ 4 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130594
	IMP CAST SZ 4 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130595
	IMP CAST SZ 5 FEM LT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130596
	IMP CAST SZ 5 FEM RT STEMMED
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	130815
	IMP CUP CAST 56 X 68 CNSR+
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	131199
	IMP CAST SZ 75 FEM RT PRIM NP
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131495
	IMP BASE SZ 3/2+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131496
	IMP BASE SZ 4/3+ KNE CC ADV
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131648
	INST CAST TRL FEM LT SZ 1
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131649
	INST CAST TRL FEM RT SZ 1
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131650
	INST CAST TRL FEM LT SZ 2
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131651
	INST CAST TRL FEM RT SZ 2
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131652
	INST CAST TRL FEM LT SZ 3
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131653
	INST CAST TRL FEM RT SZ 3
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131654
	INST CAST TRL FEM LT SZ 4
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131655
	INST CAST TRL FEM RT SZ 4
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131656
	INST CAST TRL FEM LT SZ 5
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	131657
	INST CAST TRL FEM RT SZ 5
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	132599
	INST CAST TRL FEM RT SZ 1.5
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	132744
	COMP HD 36-37MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132747
	COMP HD 42-43MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132748
	COMP HD 44-45MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132749
	COMP HD 46-47MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132909
	COMP HD 48-49MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132910
	COMP HD 50-51MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132911
	COMP HD 52-53MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132912
	COMP HD 54-55MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-4
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	132913
	COMP HD 56-57MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	132963
	COMP HD 60-61MM HIP CC BPLR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	134744
	IMP CAST SZ 2 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134745
	IMP CAST SZ 2 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134746
	IMP CAST SZ 3 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134747
	IMP CAST SZ 3 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134748
	IMP CAST SZ 4 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134749
	IMP CAST SZ 4 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134878
	IMP CAST POR SZ 2 FEM LT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134879
	IMP CAST POR SZ 2 FEM RT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134880
	IMP CAST POR SZ 3 FEM LT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134881
	IMP CAST POR SZ 3 FEM RT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134882
	IMP CAST POR SZ 4 FEM LT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134883
	IMP CAST POR SZ 4 FEM RT KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134898
	INST CAST TRL FEM LT SZ 2
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134899
	INST CAST TRL FEM RT SZ 2
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134900
	INST CAST TRL FEM LT SZ 3
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134901
	INST CAST TRL FEM RT SZ 3
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134902
	INST CAST TRL FEM LT SZ 4
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	134903
	INST CAST TRL FEM RT SZ 4
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	137941
	IMP CAST SZ 1 FEM LT NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	137942
	IMP CAST SZ 2 FEM LT NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	137945
	IMP CAST SZ 1 FEM RT NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	137946
	IMP CAST SZ 2 FEM RT NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138066
	IMP CAST SZ 1 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138067
	IMP CAST SZ 1 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138068
	IMP CAST SZ 2 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138069
	IMP CAST SZ 2 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138070
	IMP CAST SZ 3 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138071
	IMP CAST SZ 3 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138072
	IMP CAST SZ 4 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138073
	IMP CAST SZ 4 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138074
	IMP CAST SZ 5 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138075
	IMP CAST SZ 5 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138076
	IMP CAST SZ 6 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138077
	IMP CAST SZ 6 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138078
	IMP CAST SZ 7 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138079
	IMP CAST SZ 7 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-5
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	138080
	IMP CAST SZ 8 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138081
	IMP CAST SZ 8 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138090
	IMP CAST SZ 1 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138091
	IMP CAST SZ 1 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138092
	IMP CAST SZ 2 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138093
	IMP CAST SZ 2 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138094
	IMP CAST SZ 3 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138095
	IMP CAST SZ 3 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138096
	IMP CAST SZ 4 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138097
	IMP CAST SZ 4 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138098
	IMP CAST SZ 5 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138099
	IMP CAST SZ 5 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138100
	IMP CAST SZ 6 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138101
	IMP CAST SZ 6 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138102
	IMP CAST SZ 7 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138103
	IMP CAST SZ 7 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138104
	IMP CAST SZ 8 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138105
	IMP CAST SZ 8 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138106
	IMP CAST SZ 3 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138107
	IMP CAST SZ 3 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138108
	IMP CAST SZ 4 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138109
	IMP CAST SZ 4 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138110
	IMP CAST SZ 5 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138111
	IMP CAST SZ 5 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138112
	IMP CAST SZ 6 FEM LT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	138113
	IMP CAST SZ 6 FEM RT KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	140100
	COMP HD 40-41MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140101
	COMP HD 42-43MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140102
	COMP HD 44-45MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140103
	COMP HD 46-47MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140104
	COMP HD 48-49MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140105
	COMP HD 50-51MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140106
	COMP HD 52-53MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	140107
	COMP HD 54-55MM RED HIP CC
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	141811
	IMP BASE SZ 3 KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142255
	IMP CAST SZ 1 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142256
	IMP CAST SZ 1 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142257
	IMP CAST SZ 2 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-6
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	142258
	IMP CAST SZ 2 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142259
	IMP CAST SZ 2+ LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142260
	IMP CAST SZ 2+ RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142261
	IMP CAST SZ 3 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142262
	IMP CAST SZ 3 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142263
	IMP CAST SZ 4 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142264
	IMP CAST SZ 4 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142265
	IMP CAST SZ 5 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142266
	IMP CAST SZ 5 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142267
	IMP CAST SZ 6 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142268
	IMP CAST SZ 6 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142269
	IMP CAST SZ 6+ LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142270
	IMP CAST SZ 6+ RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142271
	IMP CAST SZ 7 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142272
	IMP CAST SZ 7 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142273
	IMP CAST SZ 8 LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142274
	IMP CAST SZ 8 RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142275
	IMP CAST SZ 8+ LT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142276
	IMP CAST SZ 8+ RT TIB BASE KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142844
	IMP BASE SZ 1 KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142845
	IMP BASE SZ 2 KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142847
	IMP BASE SZ 4 KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142848
	IMP BASE SZ 5 KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142849
	IMP BASE SZ 5+ KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	IMP CAST SZ 1 RX FEM NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142894
	IMP CAST SZ 3 RX FEM NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142895
	IMP CAST SZ 4 RX FEM NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142896
	IMP CAST SZ 5 RX FEM NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	142899
	IMP CAST SZ 3 RS FEM NP KNE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	143472
	IMP CAST 29MM PAT KNE CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	143473
	IMP CAST 32MM PAT KNE CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	143474
	IMP CAST 35MM PAT KNE CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	144723
	IMP BASE SZ 1+ KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	144724
	IMP BASE SZ 2+ KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	144725
	IMP BASE SZ 3+ KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	144726
	IMP BASE SZ 4+ KNE CC 913 CST
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145832
	IMP CAST SZ 2 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145833
	IMP CAST SZ 2 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-7
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	145834
	IMP CAST SZ 3 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145835
	IMP CAST SZ 3 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145836
	IMP CAST SZ 4 FEM LT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145837
	IMP CAST SZ 4 FEM RT NP KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145838
	IMP CAST SZ 2 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145839
	IMP CAST SZ 2 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145840
	IMP CAST SZ 3 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145841
	IMP CAST SZ 3 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145842
	IMP CAST SZ 4 FEM LT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145843
	IMP CAST SZ 4 FEM RT PC KNE CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	145950
	IMP CUP CAST 36 X 42 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145951
	IMP CUP CAST 38 X 44 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145952
	IMP CUP CAST 40 X 46 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145953
	IMP CUP CAST 42 X 48 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145954
	IMP CUP CAST 44 X 50 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145955
	IMP CUP CAST 46 X 52 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145956
	IMP CUP CAST 48 X 54 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145957
	IMP CUP CAST 50 X 56 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145958
	IMP CUP CAST 52 X 58 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145959
	IMP CUP CAST 54 X 60 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145960
	IMP CUP CAST 56 X 62 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145961
	IMP CUP CAST 58 X 64 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	145962
	IMP CUP CAST 60 X 66 CNSR
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	146164
	IMP BASE TIB SZ 1 CASTING CC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146165
	IMP BASE TIB SZ 5 / 4+ CASTING
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146166
	IMP BASE TIB SZ 6 / 5+ CASTING
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146167
	IMP CAST TIB SZ 2.5 TIB BASE
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146481
	IMP BASE TIB SZ 2 / 1+ CASTING
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146482
	IMP BASE TIB SZ 3 / 2+ CASTING
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146483
	IMP BASE TIB SZ 4 / 3+ CASTING
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146606
	IMP BASE SZ 2+ / 3 KNE CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146607
	IMP BASE SZ 3+ / 4 KNE CC ADVC
	IC
	CM95
	WO
	 $    [***]
	 $    [***]

	146805
	IMP SPIKED CUP SOLID 56MM OD
	IC
	CM14
	WO
	 $    [***]
	 $    [***]

	3110004120
	CASTING SHELL BIPOLAR 41
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3110004320
	CASTING SHELL BIPOLAR 43
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3110004520
	CASTING SHELL BIPOLAR 45
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3110004820
	CASTING SHELL BIPOLAR 48
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3110005020
	CASTING SHELL BIPOLAR 50
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

A-8
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

	
							
	3110005320
	CASTING SHELL BIPOLAR 53
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3608000420
	CAST HEMI 43/47MM
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3608000820
	CAST HEMI 48/52MM
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

	3608001220
	CAST HEMI 53/57MM
	IC
	CM64
	WO
	 $    [***]
	 $    [***]

A-9
[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

EXHIBIT B
Price Adjustments

The price of the Products shall be altered to reflect any movements in the constituent elements of the alloy. 

The metal mechanism is then applied as per the example below:

The Alloy Base Price (ABP) is calculated for each part, and is relative to the alloy portion of the sales price for the part. Each main element (Co, Mo, and Cr) is then referenced and its movement versus the base is recorded at the time of setting the pricing for the next agreement.

Cobalt with Base Price (CoBP) at $19 per lb. represents 75.75% of the Alloy Base Price (ABP) per piece.
Therefore, if the latest cobalt price has increased by 5% v the CoBP then: 

ABP changes by 75.75% X 5% = 3.788%

Molybdenum with Base Price (MoBP) at $18.64 per lb represents 14.66% of the ABP per piece.  Therefore, if the latest molybdenum price has reduced by 10% v the MoBP then: 

ABP changes by 14.66% X -10% = -1.466%

Chromium with Base Price (CrBP) at $3.65 per lb represents 9.59% of the ABP per piece.  Therefore, if the latest chromium price has increased by 20% v the CrBP then: 
    
ABP changes by 9.59% X 20% = 1.918%

ASSUMING THE ABP is $10.00 ON A PARTICULAR PART THEN THE PRICE WILL CHANGE BY 

3.788% + -1.466% + 1.918% = 4.24% 
    
$10.00 X  4.24% = $0.42 PER PART

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}]]